Lexicon Genetics released data highlighting potential therapeutic targets related to its collaboration with Genentech. These target discoveries were made through the collaboration between the two companies that was initiated in December 2002 and expanded in November 2005 to advance the R&D and commercialization of new biologic drugs. Lexicon has developed antibodies for one of these targets, designated LG842, which it is now advancing through preclinical research. The data revealed that...